Dutch biotech Laigo Bio has launched with 11.5 million euros ($12.7 million) in seed financing to progress its SureTAC ...

Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...

Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistan ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an announcement. Shanghai Henlius Biotech, Inc. announced that its ...

Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

The rising global cancer burden continues to drive market expansion, with WHO reporting 20 million new cases and 9.7 million ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

IDEAYA Biosciences, Inc. ( IDYA) Citi Annual Global Healthcare Conference 2025 December 2, 2025 9:00 AM EST ...